Esophageal Cancer, Gastric Cancer
Conditions
Keywords
Gastric Cancer, Gastroesophageal junction cancer, Esophageal Cancer, Surgery, Chemotherapy, Radiotherapy, Antitargeted drug, Inmunotherapy
Brief summary
This study aims to development of a database through a web page for epidemiological and clinical research purposes that is accessible to members of the AGAMENON - SEOM group that guarantees a rigorous collection, exploitation and analysis of the data and information contained, increases the knowledge of esophageal and stomach cancer in order to optimize the management, treatment and evolution of patients, the possibility of comparing variables with those of other series or groups, and promotes the quality of scientific publications.
Detailed description
Patient data will be collected from medical records retrospectively.
Interventions
PROCEDURESurgery
Surgery
DRUGChemotherapy, anti-targeted agents and immunotherapy
Chemotherapy, anti-targeted agents and immunotherapy
RADIATIONRadiotherapy
Radiotherapy
Sponsors
Fundación Sociedad Española de Oncologia Médica
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 100 Years
Healthy volunteers
No
Inclusion criteria
* Adult patient (≥18 years) diagnosed with carcinoma of the esophagus, gastroesophageal junction and stomach, including all histologic subtypes, with or without erbB2 overexpression (and tumors in which this data is unknown). * Follow-up of at least 3 months with clinical information during this period, exempting patients with early death from any cause.
Exclusion criteria
* A patient for whom, for whatever reason, the information necessary to complete the database cannot be known or obtained.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Diagnostic and therapeutic approach | Up to 12 months | To evaluate survival (time in months) according to treatment of esophagogastric cancer in all stages, patients, and contexts. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Risk factors | Up to 12 months | To study risk factors associated with each subtype of esophagogastric cancer and localization. |
| Pathological features | Up to 12 months | To evaluate the pathological features (TNM, grade, histological response) The TNM is measured with the American Joint Committee on Cancer (AJCC) staging system. The grade is classified with the WHO scale. Histological response is measured with Becker classification. |
| Clinical and diagnostic approach | Up to 12 months | To know the diagnostic approch according to the center, type of studies performed: endoscopy, CT, echoendoscopy and/or PET/CT. From these studies it will be collected whether they have been carried out and where they visualise tumour. The use of scales and measurements is therefore not appropriate. |
| Epidemiological profiles | Up to 12 months | To know the epidemiological profiles of esophagogastric cancer in Spain: temporal and regional trends, morbidity, and mortality. |
| Validate and compare prognostic models | Up to 12 months | To validate and compare the three prognostic models for advanced esophagogastric adenocarcinoma: The Royal Marsden Hospital index (Chau et al, 2004), and the models of Kim (2008) and Lee (2007), in a real sample of patients based on daily clinical practice. |
| Prognostic factors | Up to 12 months | To analyze the prognostic factors in this population and build a predictive and/or prognostic model. |
| Create and validate a predictive model | Up to 12 months | To create and validate a predictive model of early mortality. |
| Treatments adjusted to prognostic variables | Up to 12 months | To compare treatments adjusted to prognostic variables and baseline characteristics. |
Countries
Spain
Contacts
Primary ContactPaula Dr Jiménez Fonseca, MD-PhD
Outcome results
None listed